Embecta Corp (EMBC)

$12.46

-0.11

(-0.88%)

Market is closed - opens 7 PM, 20 Jun 2024

Insights on Embecta Corp

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 277.3M → 287.2M (in $), with an average increase of 3.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 6.0M → 28.9M (in $), with an average increase of 50.3% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 32.1% return, outperforming this stock by 82.2%

Performance

  • $12.41
    $12.68
    $12.46
    downward going graph

    0.4%

    Downside

    Day's Volatility :2.09%

    Upside

    1.7%

    downward going graph
  • $9.70
    $24.10
    $12.46
    downward going graph

    22.15%

    Downside

    52 Weeks Volatility :59.75%

    Upside

    48.3%

    downward going graph

Returns

PeriodEmbecta CorpSector (Health Care)Index (Russel 2000)
3 Months
-3.04%
0.1%
0.0%
6 Months
-30.35%
8.3%
0.0%
1 Year
-49.76%
10.4%
0.0%
3 Years
-58.44%
17.9%
-20.9%

Highlights

Market Capitalization
724.9M
Book Value
- $13.35
Dividend Share
0.6
Dividend Yield
4.77%
Earnings Per Share (EPS)
1.22
PE Ratio
10.3
Wall Street Target Price
15.0
Profit Margin
6.2%
Operating Margin TTM
25.0%
Return On Assets TTM
9.74%
Return On Equity TTM
0.0%
Revenue TTM
1.1B
Revenue Per Share TTM
19.72
Quarterly Revenue Growth YOY
3.5999999999999996%
Gross Profit TTM
774.9M
EBITDA
223.0M
Diluted Eps TTM
1.22
Quarterly Earnings Growth YOY
1.08
EPS Estimate Current Year
2.27
EPS Estimate Next Year
2.26
EPS Estimate Current Quarter
0.4
EPS Estimate Next Quarter
0.55

Analyst Recommendation

Sell
    0
    0%Buy
    44%Hold
    55%Sell
Based on 9 Wall street analysts offering stock ratings for Embecta Corp(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
4
4
4
Sell
5
5
5

Analyst Forecast

What analysts predicted

Upside of 20.39%

Current $12.46
Target $15.00

Company Financials

FY19Y/Y Change
Revenue
1.1B
-
Net Income
432.0M
-
Net Profit Margin
38.95%
-
FY20Y/Y Change
Revenue
1.1B
↓ 2.12%
Net Income
427.6M
↓ 1.02%
Net Profit Margin
39.39%
↑ 0.44%
FY21Y/Y Change
Revenue
1.2B
↑ 7.32%
Net Income
414.8M
↓ 2.99%
Net Profit Margin
35.61%
↓ 3.78%
FY22Y/Y Change
Revenue
1.1B
↓ 3.05%
Net Income
223.6M
↓ 46.09%
Net Profit Margin
19.8%
↓ 15.81%
FY23Y/Y Change
Revenue
1.1B
↓ 0.77%
Net Income
70.4M
↓ 68.52%
Net Profit Margin
6.28%
↓ 13.52%
Q4 FY22Q/Q Change
Revenue
188.8M
↓ 31.25%
Net Income
55.4M
↓ 422.09%
Net Profit Margin
29.34%
↑ 35.6%
Q1 FY23Q/Q Change
Revenue
277.1M
↑ 46.77%
Net Income
14.0M
↓ 74.73%
Net Profit Margin
5.05%
↓ 24.29%
Q2 FY23Q/Q Change
Revenue
286.1M
↑ 3.25%
Net Income
15.2M
↑ 8.57%
Net Profit Margin
5.31%
↑ 0.26%
Q3 FY23Q/Q Change
Revenue
281.9M
↓ 1.47%
Net Income
6.0M
↓ 60.53%
Net Profit Margin
2.13%
↓ 3.18%
Q4 FY23Q/Q Change
Revenue
277.3M
↓ 1.63%
Net Income
20.1M
↑ 235.0%
Net Profit Margin
7.25%
↑ 5.12%
Q1 FY24Q/Q Change
Revenue
287.2M
↑ 3.57%
Net Income
28.9M
↑ 43.78%
Net Profit Margin
10.06%
↑ 2.81%
FY19Y/Y Change
Total Assets
745.0M
-
Total Liabilities
126.0M
-
FY20Y/Y Change
Total Assets
738.0M
↓ 0.94%
Total Liabilities
166.0M
↑ 31.75%
FY21Y/Y Change
Total Assets
788.0M
↑ 6.78%
Total Liabilities
194.0M
↑ 16.87%
FY22Y/Y Change
Total Assets
1.1B
↑ 37.87%
Total Liabilities
2.0B
↑ 919.48%
FY23Y/Y Change
Total Assets
1.2B
↑ 11.78%
Total Liabilities
2.0B
↑ 2.95%
Q4 FY22Q/Q Change
Total Assets
1.2B
↑ 10.17%
Total Liabilities
2.0B
↑ 2.79%
Q1 FY23Q/Q Change
Total Assets
1.2B
↑ 1.09%
Total Liabilities
2.0B
↓ 0.02%
Q2 FY23Q/Q Change
Total Assets
1.3B
↑ 3.48%
Total Liabilities
2.1B
↑ 1.42%
Q3 FY23Q/Q Change
Total Assets
1.2B
↓ 3.01%
Total Liabilities
2.0B
↓ 1.23%
Q4 FY23Q/Q Change
Total Assets
1.2B
↑ 0.28%
Total Liabilities
2.0B
↓ 1.22%
Q1 FY24Q/Q Change
Total Assets
1.2B
↓ 1.49%
Total Liabilities
2.0B
↓ 2.09%
FY19Y/Y Change
Operating Cash Flow
505.0M
-
Investing Cash Flow
-69.0M
-
Financing Cash Flow
-436.0M
-
FY20Y/Y Change
Operating Cash Flow
498.5M
↓ 1.29%
Investing Cash Flow
-42.0M
↓ 39.13%
Financing Cash Flow
-456.6M
↑ 4.72%
FY21Y/Y Change
Operating Cash Flow
456.0M
↓ 8.53%
Investing Cash Flow
-39.0M
↓ 7.14%
Financing Cash Flow
-417.0M
↓ 8.67%
FY22Y/Y Change
Operating Cash Flow
412.2M
↓ 9.61%
Investing Cash Flow
-24.0M
↓ 38.46%
Financing Cash Flow
-48.0M
↓ 88.49%
Q4 FY22Q/Q Change
Operating Cash Flow
60.4M
↑ 4.14%
Investing Cash Flow
-4.7M
↓ 45.35%
Financing Cash Flow
-6.1M
↓ 14.08%
Q1 FY23Q/Q Change
Operating Cash Flow
-13.0M
↓ 121.52%
Investing Cash Flow
-5.8M
↑ 23.4%
Financing Cash Flow
-20.7M
↑ 239.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-9.3M
↓ 28.46%
Investing Cash Flow
-6.8M
↑ 17.24%
Financing Cash Flow
-12.2M
↓ 41.06%

Technicals Summary

Sell

Neutral

Buy

Embecta Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Embecta Corp
Embecta Corp
-10.55%
-30.35%
-49.76%
-58.44%
-58.44%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
8.74%
29.57%
32.69%
45.97%
150.03%
Resmed Inc.
Resmed Inc.
-2.96%
22.29%
-2.09%
-11.38%
76.1%
Becton, Dickinson And Company
Becton, Dickinson And Company
-1.43%
-2.86%
-8.87%
-2.95%
-1.89%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-6.04%
-10.11%
-12.03%
-9.93%
164.36%
Alcon Ag
Alcon Ag
1.4%
18.16%
11.11%
26.19%
50.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Embecta Corp
Embecta Corp
10.3
10.3
NA
2.27
0.0
0.1
0.05
-13.35
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
76.86
76.86
7.13
6.29
0.16
0.08
NA
39.37
Resmed Inc.
Resmed Inc.
32.57
32.57
1.75
7.73
0.22
0.12
0.01
31.52
Becton, Dickinson And Company
Becton, Dickinson And Company
50.05
50.05
1.34
13.05
0.05
0.03
0.02
88.74
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
44.08
44.08
6.72
7.76
0.21
0.11
0.0
36.72
Alcon Ag
Alcon Ag
42.98
42.98
4.59
3.07
0.05
0.02
0.0
42.13
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Embecta Corp
Embecta Corp
Sell
$724.9M
-58.44%
10.3
6.2%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$151.0B
150.03%
76.86
27.16%
Resmed Inc.
Resmed Inc.
Buy
$31.1B
76.1%
32.57
20.91%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.5B
-1.89%
50.05
6.76%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$24.4B
164.36%
44.08
19.42%
Alcon Ag
Alcon Ag
Buy
$44.7B
50.77%
42.98
10.96%

Institutional Holdings

  • BlackRock Inc

    16.09%
  • Vanguard Group Inc

    12.51%
  • River Road Asset Management, LLC

    5.98%
  • Millennium Management LLC

    5.61%
  • American Century Companies Inc

    5.45%
  • Yacktman Asset Management Co

    4.88%

Company Information

Organization
Embecta Corp
Employees
2200
CEO
Mr. Devdatt Kurdikar
Industry
Healthcare

FAQs